3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer.

      1

      Immunotherapy

      Future Medicine Ltd

      Imlygic, T-VEC, oncolytic immunotherapy

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Interviewed by Ellen Clarke, Commissioning Editor, Future Science Group. Robert Coffin is co-founder and CEO of Replimune. Previously he was Founder and CTO of BioVex Inc, a spin out from his research group at University College London in 1999. He was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal Phase 3 studies in melanoma and head and neck cancer. BioVex was acquired by Amgen in 2011 where he was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in USA. He was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.

          Related collections

          Author and article information

          Journal
          Immunotherapy
          Immunotherapy
          Future Medicine Ltd
          1750-7448
          1750-743X
          Feb 2016
          : 8
          : 2
          Affiliations
          [1 ] Replimune Ltd, The Oxford Science Park Magdalen Centre, Robinson Avenue, Oxford OX4 4GA.
          Article
          10.2217/imt.15.116
          26799112

          oncolytic immunotherapy, T-VEC, Imlygic

          Comments

          Comment on this article